Please assess the completion status of the following clinical trial:

Trial Title: Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients scheduled for CABG (males or non-pregnant females)~2. \> 18 years old with at least one vein graft planned~3. Able to provide written informed consent~Exclusion Criteria:~1. Patients who, in the investigator's or attending surgeon's opinion, are unsuitable for anticoagulation due to their clinical status~2. Documented history of allergy to iodinated contrast media, warfarin, or argatroban~3. Chronic renal impairment with CrCl\<60 ml/min~4. Recent bleeding episode~5. Congestive Heart Failure (EF\< 30%)~6. Bleeding diathesis or known thrombophilic disorder~7. Atrial fibrillation or other condition requiring anticoagulation at the time of enrollment~8. Documented history of heparin induced thrombocytopenia~9. Clinical suspicion of HIT at the time of randomization, defined as 50% decrease in Platelet count from last heparin exposure or Platelet count \<100,000/ml~10. Hepatic dysfunction (defined as LFTs \> 3 times the upper limit of normal)~11. Patients with a history of bleeding complications post-CABG~12. Hemorrhagic stroke~13. Gastrointestinal bleeding~14. Requirement for fresh frozen plasma~15. Recent central nervous system or ophthalmic surgery~16. Aneurysm~17. History of psychosis or senility~18. Malignant hypertension~19. Clinically significant pericarditis or pericardial effusion~20. Bacterial endocarditis~21. Hematocrit \< 24%~22. Valve replacement or repair at time of CABG~23. Subjects with signs or symptoms of possible Transient Ischemic Attack or stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heparin PF4 antibody positive -Drug (argatroban and warfarin) (Type: EXPERIMENTAL): Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
- Heparin PF4 antibody positive no drug (Type: NO_INTERVENTION): Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
- Heparin PF4 antibody negative (Type: NO_INTERVENTION): Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication

Based on this trial design, predict the completion outcome and termination type (if applicable).